Sorrento Therapeutics (SRNE) Competitors $0.0015 0.00 (-34.78%) As of 08/7/2025 03:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. AIM, BCTX, KTTA, ADIL, ENSC, INM, GRI, GLTO, ORGS, and MTNBShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include AIM ImmunoTech (AIM), Briacell Therap (BCTX), Pasithea Therapeutics (KTTA), Adial Pharmaceuticals (ADIL), Ensysce Biosciences (ENSC), InMed Pharmaceuticals (INM), GRI Bio (GRI), Galecto (GLTO), Orgenesis (ORGS), and Matinas Biopharma (MTNB). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors AIM ImmunoTech Briacell Therap Pasithea Therapeutics Adial Pharmaceuticals Ensysce Biosciences InMed Pharmaceuticals GRI Bio Galecto Orgenesis Matinas Biopharma AIM ImmunoTech (NYSE:AIM) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Which has stronger earnings & valuation, AIM or SRNE? AIM ImmunoTech has higher earnings, but lower revenue than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIM ImmunoTech$146K14.23-$28.96M-$24.00-0.11Sorrento Therapeutics$60.32M0.01-$572.84MN/AN/A Do analysts prefer AIM or SRNE? AIM ImmunoTech currently has a consensus target price of $275.00, indicating a potential upside of 10,010.29%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, equities research analysts clearly believe AIM ImmunoTech is more favorable than Sorrento Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is AIM or SRNE more profitable? Sorrento Therapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Sorrento Therapeutics' return on equity of 0.00% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets AIM ImmunoTech-12,594.21% -421.73% -147.54% Sorrento Therapeutics N/A N/A N/A Do insiders and institutionals believe in AIM or SRNE? 12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, AIM or SRNE? AIM ImmunoTech has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Does the media refer more to AIM or SRNE? In the previous week, AIM ImmunoTech had 2 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for AIM ImmunoTech and 0 mentions for Sorrento Therapeutics. AIM ImmunoTech's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score. Company Overall Sentiment AIM ImmunoTech Neutral Sorrento Therapeutics Neutral SummaryAIM ImmunoTech beats Sorrento Therapeutics on 8 of the 13 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$827K$283.63M$5.48B$9.56BDividend YieldN/AN/A3.99%4.17%P/E RatioN/AN/A29.9325.14Price / Sales0.01461.90375.2276.13Price / CashN/A22.4435.9458.58Price / BookN/A9.538.105.59Net Income-$572.84M-$115.81M$3.26B$265.48M7 Day PerformanceN/A1.09%0.68%1.22%1 Month PerformanceN/A8.37%2.45%0.39%1 Year PerformanceN/A-3.24%27.72%23.47% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.8853 of 5 stars$0.00-34.8%N/A-81.3%$827K$60.32M0.00800AIMAIM ImmunoTech1.1479 of 5 stars$7.20-14.3%$275.00+3,719.4%-91.4%$5.50M$146K-15.3220Gap UpHigh Trading VolumeBCTXBriacell Therap1.6495 of 5 stars$0.81+0.9%$32.00+3,865.8%-92.4%$5.42MN/A-0.108Stock SplitKTTAPasithea TherapeuticsN/A$0.75+2.6%N/A-85.3%$5.40MN/A-0.073Upcoming EarningsADILAdial Pharmaceuticals2.8399 of 5 stars$0.63+22.6%$8.00+1,169.8%-61.0%$5.36MN/A-0.4320Upcoming EarningsGap UpHigh Trading VolumeENSCEnsysce Biosciences0.5016 of 5 stars$2.29+2.2%N/A-62.8%$5.31M$5.21M-0.3510Positive NewsUpcoming EarningsINMInMed Pharmaceuticals0.0738 of 5 stars$2.64flatN/A-16.0%$5.29M$4.60M-0.2210GRIGRI Bio2.0049 of 5 stars$2.14+7.5%$22.00+928.0%-84.0%$4.97MN/A-0.191Upcoming EarningsShort Interest ↑Gap UpGLTOGalecto2.9079 of 5 stars$3.77+0.5%$10.00+165.3%-72.8%$4.96MN/A-0.2440Positive NewsEarnings ReportUpcoming EarningsGap UpORGSOrgenesis1.2236 of 5 stars$1.00flatN/AN/A$4.80M$662K0.00150MTNBMatinas Biopharma0.6009 of 5 stars$0.930.0%N/AN/A$4.73MN/A-0.1930Gap Up Related Companies and Tools Related Companies AIM ImmunoTech Competitors Briacell Therap Competitors Pasithea Therapeutics Competitors Adial Pharmaceuticals Competitors Ensysce Biosciences Competitors InMed Pharmaceuticals Competitors GRI Bio Competitors Galecto Competitors Orgenesis Competitors Matinas Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRNE Stock Alerts